Coherus BioSciences, Inc.
http://www.coherus.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Coherus BioSciences, Inc.
Coherus Positive And Up For The Fight Amid Amneal Pegfilgrastim Deals
Coherus BioSciences feels its bearing and clout in the US pegfilgrastim market will stand it in good stead as other players scrabble to compete on the more lucrative formulations of Amgen’s Neulasta.
Celltrion Offers 85% Discount For Adalimumab Biosimilar In US
Celltrion joins a number of other adalimumab competitors with dual pricing strategies as Humira biosimilars finally gain some traction in the US market.
Corbus And Janux Lead Q1’s Small-Cap Winners
Corbus has presence in both antibody drug conjugates and obesity, and was the stand-out small-cap target for investors with a fivefold increase in its share price in Q1.
Clasp Launches With $150m To Develop Personalized T-Cell Engagers
Clasp Therapeutics, which emerged from labs at Johns Hopkins University and was incubated by a pair of venture capital investors, plans to achieve a clinical trial readout with its series A cash.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- InteKrin Therapeutics, Inc.
- Coherus Intermediate Corp
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice